We would like to inform you that we have completed the first part of the study with a single, escalating dose (FIH, SAD) (Part A), of the innovative antidiabetic drug.

 

We would like to inform you that we have completed the first part of the study with a single, escalating dose (FIH, SAD) (Part A), of the innovative antidiabetic drug. The project was implemented in cooperation with a Polish pharmaceutical company. The new therapy aims to reduce insulin resistance and to regulate the chronic high blood glucose level. Due to the state of the pandemic, the study was conducted in accordance with the highest sanitary standards as well as procedures related to the monitoring of the epidemic state. This approach, combined with the principles of GCP, ensured the safety and well-being of our patients. Soon we are starting the second part of the study (hello B0) with multiple, escalating dose of the new drug.

Go back

News

International Clinical Trials Day

On 28th of June, 2019 we attended the annual conference on the occassion of International Clinical Trials Day titled "On the verge of changes".

Read more …

TransCelerate accreditation

To improve our trainings system, we joined „GCP Mutual Recognition Program" and were accredited by TransCelerate Biopharma Inc

Read more …

Happy Easter!

To all our employees, co-workers, clients and patients we would like to express our best wishes of joyful and peaceful Easter.

Read more …

Pediatrics Clinical Trials - conference

On 16th of April, 2019 we attended an interesting conference concerning clinical trials in pediatrics organised by GCPpl society.

Read more …

Personal Data Security in Clinical Trials

On 21st of March, 2019 our representatives attended workshops concerning personal data security in clinical trials.

Read more …

About Us | Services | Our Site | Partners | Smoking Risk Study | Contact Us

Early Phase Clinical Trials

2022 © Bio Research Group. All rights reserved.

 

scroll to top ▲